Compare Match Group Inc (MTCH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Neurocrine Biosciences Inc — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Match Group Inc pays a 1.94% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MTCH | NBIX | |
|---|---|---|
Market Cap | $9.45B | $15.77B |
Sector | Media | Health |
52-Week High | $42.44 | $185.50 |
52-Week Low | $28.90 | $123.10 |
Enterprise Value | $12.41B | $15.78B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near the analyst low target of $41.00. The stock shows a bullish technical trend with recent earnings beating expectations in Q2 2026. Fundamentals are solid with a P/E of 14.59, net income margin of 20.17%, and strong cash flow growth. Recent news highlights AI-driven product innovations at Tinder and institutional buying interest.
Outlook is positive with a consensus price target of $42.50, offering modest upside. Key opportunities include AI integration and user growth, while risks involve high debt levels and competitive pressures in the dating app market. The stock presents a balanced risk-reward profile for growth-oriented investors.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
